{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:48:54Z","timestamp":1772815734803,"version":"3.50.1"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"6","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US Agency for International Development and the US Centers for Disease Control and Prevention","award":["OGH09-011:CGH10-1010196"],"award-info":[{"award-number":["OGH09-011:CGH10-1010196"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,1]]},"DOI":"10.1093\/jac\/dkx022","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T08:23:51Z","timestamp":1485764631000},"page":"1678-1687","source":"Crossref","is-referenced-by-count":25,"title":["Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic\/pharmacodynamic parameters"],"prefix":"10.1093","volume":"72","author":[{"given":"Joseph S.","family":"Cavanaugh","sequence":"first","affiliation":[{"name":"United States Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruwen","family":"Jou","sequence":"additional","affiliation":[{"name":"Taiwan Centers for Disease Control, Taipei, Taiwan, Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"Taiwan Centers for Disease Control, Taipei, Taiwan, Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Dalton","sequence":"additional","affiliation":[{"name":"United States Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Kurbatova","sequence":"additional","affiliation":[{"name":"United States Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Ershova","sequence":"additional","affiliation":[{"name":"United States Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Peter","family":"Cegielski","sequence":"additional","affiliation":[{"name":"United States Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Global PETTS Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"key":"key\n\t\t\t\t20180313122808_dkx022-B1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijid.2014.12.031","article-title":"Repurposing\u2014a ray of hope in tackling extensively drug resistance in tuberculosis","volume":"32","author":"Maitra","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B2","volume-title":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis","year":"2015"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B3","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/S0140-6736(12)60734-X","article-title":"Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study","volume":"380","author":"Dalton","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B4","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1128\/AAC.46.8.2720-2722.2002","article-title":"Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis","volume":"46","author":"Palomino","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B5","author":"Martin","year":"2012"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B6","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","article-title":"Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index","volume":"14","author":"Wasserman","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1183\/09031936.00114812","article-title":"Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis","volume":"42","author":"Alsaad","year":"2013","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B8","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1128\/AAC.01658-08","article-title":"Tuberculosis and trimethoprim-sulfamethoxazole","volume":"53","author":"Forgacs","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B9","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1128\/AAC.02995-14","article-title":"Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis","volume":"58","author":"Davies Forsman","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B10","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/dkr501","article-title":"Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan","volume":"67","author":"Huang","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B11","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1093\/jac\/dks306","article-title":"Sulfamethoxazole enhances the antimycobacterial activity of rifampicin","volume":"67","author":"Macingwana","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B12","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1128\/AAC.00029-10","article-title":"Mycobacterium tuberculosis and sulfamethoxazole susceptibility","volume":"54","author":"Ong","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B13","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1128\/AAC.01683-13","article-title":"In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in France","volume":"57","author":"Ameen","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B14","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1128\/AAC.01101-15","article-title":"Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis","volume":"59","author":"Ogwang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B15","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1128\/AAC.01301-08","article-title":"Dosing regimens of cotrimoxazole (trimethoprim-sulfamethoxazole) for melioidosis","volume":"53","author":"Cheng","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ijantimicag.2013.07.011","article-title":"Trimethoprim\/sulfamethoxazole susceptibility of Mycobacterium tuberculosis","volume":"42","author":"Alsaad","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B17"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B18","first-page":"530815.","article-title":"Mefloquine and its enantiomers are active against Mycobacterium tuberculosis in vitro and in macrophages","volume":"2014","author":"Bermudez","year":"2014","journal-title":"Tuberc Res Treat"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B19","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1183\/13993003.00321-2015","article-title":"Mefloquine as a potential drug against multidrug-resistant tuberculosis","volume":"46","author":"Krieger","year":"2015","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/1475-2875-12-443","article-title":"Gender-specific distribution of mefloquine in the blood following the administration of therapeutic doses","volume":"12","author":"Wernsdorfer","year":"2013","journal-title":"Malar J"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ijantimicag.2006.10.013","article-title":"In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis","volume":"29","author":"Martins","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.47.3.917-922.2003","article-title":"Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis","volume":"47","author":"Ordway","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.clpt.6100195","article-title":"Factors affecting drug concentrations and QT interval during thioridazine therapy","volume":"82","author":"Thanacoody","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/j.1365-2125.2007.03021.x","article-title":"Thioridazine: resurrection as an antimicrobial agent?","volume":"64","author":"Thanacoody","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B25","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1128\/AAC.00120-13","article-title":"WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis","volume":"57","author":"Chang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1164\/rccm.201410-1801OC","article-title":"Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline","volume":"191","author":"Diacon","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5588\/ijtld.10.0238","article-title":"Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis","volume":"15","author":"Schon","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tube.2004.04.001","article-title":"Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid","volume":"84","author":"Nix","year":"2004","journal-title":"Tuberculosis (Edinb)"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B29","first-page":"135","article-title":"Lamprene (clofazimine) in leprosy. Basic information","volume":"50","author":"Yawalkar","year":"1979","journal-title":"Lepr Rev"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B30","first-page":"9","article-title":"Pharmacokinetics of clofazimine in healthy volunteers","volume":"55","author":"Schaad-Lanyi","year":"1987","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B31","first-page":"1083","article-title":"Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In vitro, intracellular, and in vivo studies","volume":"151","author":"Jagannath","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B32","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B33","doi-asserted-by":"crossref","first-page":"e47494.","DOI":"10.1371\/journal.pone.0047494","article-title":"Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization","volume":"7","author":"Baik","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B34","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1073\/pnas.1416951112","article-title":"Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis","volume":"112","author":"Tyagi","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B35","doi-asserted-by":"crossref","first-page":"e004143","DOI":"10.1136\/bmjopen-2013-004143","article-title":"Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies","volume":"4","author":"Hwang","year":"2014","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1586\/eri.12.96","article-title":"Reappraising the use of \u03b2-lactams to treat tuberculosis","volume":"10","author":"Kurz","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/ja.2014.94","article-title":"Mechanisms of \u03b2-lactam killing and resistance in the context of Mycobacterium tuberculosis","volume":"67","author":"Wivagg","year":"2014","journal-title":"J Antibiot"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1086\/513945","article-title":"Activity of amoxicillin\/clavulanate in patients with tuberculosis","volume":"26","author":"Chambers","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B39","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1128\/AAC.02020-12","article-title":"Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate","volume":"57","author":"Ahmed","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B40","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2003.09.023","article-title":"The vitro efficacy of \u03b2-lactam and \u03b2-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis","volume":"23","author":"Dincer","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B41","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1128\/AAC.00023-13","article-title":"In vitro and in vivo efficacy of \u03b2-lactams against replicating and slowly growing\/nonreplicating Mycobacterium tuberculosis","volume":"57","author":"Solapure","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B42","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/jac\/dks395","article-title":"Is there a place for \u03b2-lactams in the treatment of multidrug-resistant\/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin\/clavulanate","volume":"68","author":"Gonzalo","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B43","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.ijantimicag.2007.07.038","article-title":"The development of pharmacokinetically enhanced amoxicillin\/clavulanate for the management of respiratory tract infections in adults","volume":"30","author":"File","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thx.25.3.304","article-title":"Ampicillin levels in sputum, serum, and saliva","volume":"25","author":"Stewart","year":"1970","journal-title":"Thorax"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0891-5520(03)00066-7","article-title":"Intracellular pharmacodynamics of antibiotics","volume":"17","author":"Carryn","year":"2003","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B46","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1128\/AAC.00171-15","article-title":"Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis","volume":"59","author":"Davies Forsman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B47","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B48","first-page":"427","article-title":"In vitro evaluation of linezolid and meropenem against clinical isolates of multi drug resistant tuberculosis by Mycobacterial Growth Indicator Tube (MGIT) 960","volume":"25","author":"Mirza","year":"2015","journal-title":"J Coll Physicians Surg Pak"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B49","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B50","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.arbres.2015.03.012","article-title":"First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina","volume":"51","author":"Palmero","year":"2015","journal-title":"Arch Bronconeumol"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1183\/13993003.01278-2015","article-title":"Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience","volume":"47","author":"Tiberi","year":"2016","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B52","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1128\/AAC.02542-12","article-title":"Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis","volume":"57","author":"Shigyo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B53","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1021\/jm9010719","article-title":"Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance","volume":"52","author":"de Carvalho","year":"2009","journal-title":"J Med Chem"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5414\/CPP40213","article-title":"Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses","volume":"40","author":"Stockis","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B55","doi-asserted-by":"crossref","first-page":"e1002691","DOI":"10.1371\/journal.ppat.1002691","article-title":"Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis","volume":"8","author":"Lam","year":"2012","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B56","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0255-0857.150967","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis from Shenyang, north of China","volume":"33","author":"Liu","year":"2015","journal-title":"Indian J Med Microbiol"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B57","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1183\/09031936.00041314","article-title":"In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis","volume":"44","author":"Bolhuis","year":"2014","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijantimicag.2013.03.002","article-title":"In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates","volume":"42","author":"Yip","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B59","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B60","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B61","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jac\/dks078","article-title":"Daily 300\u2009mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients","volume":"67","author":"Koh","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B62","doi-asserted-by":"crossref","first-page":"16004","DOI":"10.1073\/pnas.1214188109","article-title":"Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials","volume":"109","author":"Gold","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/bmb\/ldw019","article-title":"Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs","volume":"118","author":"Maitra","year":"2016","journal-title":"Br Med Bull"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B64","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/AAC.01474-09","article-title":"New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability","volume":"54","author":"Gumbo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000323628","volume-title":"Antituberculosis Chemotherapy","author":"Donald","year":"2011"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B66","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.14.0100","article-title":"Successful \u20329-month Bangladesh regimen\u2032 for multidrug-resistant tuberculosis among over 500 consecutive patients","volume":"18","author":"Aung","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B67","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B68","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","article-title":"High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses","volume":"18","author":"Piubello","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clpt.2004.06.002","article-title":"The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283)","volume":"76","author":"Winter","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B70","first-page":"83","article-title":"Pharmacokinetics of mefloquine alone or in combination with artesunate","volume":"72","author":"Karbwang","year":"1994","journal-title":"Bull World Health Organ"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002280050351","article-title":"Food increases the bioavailability of mefloquine","volume":"53","author":"Crevoisier","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B72","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.5588\/ijtld.11.0752","article-title":"In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters","volume":"16","author":"Xu","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/44.2.209","article-title":"Inhibition of potassium transport and growth of mycobacteria exposed to clofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity","volume":"44","author":"Steel","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B74","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jps.2600781003","article-title":"Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study","volume":"78","author":"Chakraborty","year":"1989","journal-title":"J Pharm Sci"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5414\/CPP40221","article-title":"Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5\u2005g and 1\u2005g b.i.d","volume":"40","author":"Stockis","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B76","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180313122808_dkx022-B77","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/590064","article-title":"Pharmacokinetic and pharmacodynamic properties of meropenem","volume":"47","author":"Nicolau","year":"2008","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/72\/6\/1678\/24332007\/dkx022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T12:33:59Z","timestamp":1520944439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/72\/6\/1678\/3037988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":77,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,2,20]]},"published-print":{"date-parts":[[2017,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkx022","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,6]]},"published":{"date-parts":[[2017,2,20]]}}}